Healthcare Fund - Invest in DSP Healthcare Fund Regular Growth Online

DSP Healthcare Fund

This is an Equity Sectoral/Thematic, Pharma fund with S&P BSE HEALTHCARE (TRI) as its benchmark. The risk level for this fund is categorized as Very High Risk.

Total AUM

₹1,243.08 crores as of Apr 30, 2023

Age of Fund

4 years 6 months since Nov 30, 2018

Expense Ratio

2.13% as of Jun 02, 2023

Exit Load

1% upto 12 Months

Ideal holding period

10 Years+

Holdings

as of Apr 30, 2023

Sun Pharmaceutical Industries Limited

16.19%

Cipla Limited

9.73%

Apollo Hospitals Enterprise Limited

6.76%

Procter & Gamble Health Limited

5.95%

Lupin Limited

5.82%

Alkem Laboratories Limited

5.02%

Alembic Pharmaceuticals Limited

4.91%

See all 26 holdings

Rolling Returns

Bars show distribution of returns in given range for selected time period.

View performance details

Things to know before you invest

What is in DSP Healthcare Fund?

This thematic fund invests in established & upcoming companies in the pharmaceutical & healthcare space in India and internationally (primarily, the United States).
It can have up to 25% allocation to global stocks to provide access to sectors less developed or available in India.
It considers companies who 'help people get well soon' across the healthcare spectrum- including pharmaceuticals, hospitals, diagnostics etc.

Why should one invest in DSP Healthcare Fund?

Offers the potential to grow your wealth & 'earn big' returns if this theme does well (a high-risk, high-return strategy).
Favourable sector dynamics- Rising income levels, increasing health-consciousness, government policies means an increase in healthcare spending, so companies in this space could do well.
The up to 25% international exposure with low correlation to Indian healthcare companies means healthy diversification.
Can help you beat the impact of rising prices over the long-term.
Can be a suitable choice for tactical allocation.

Who should invest in DSP Healthcare Fund?

Consider this fund if you
- Are an experienced investor with a well-set core portfolio & know what you're doing.
- Are looking to tactically allocate 10-15% of your overall portfolio to very high-risk opportunities.
- Understand that there is very high risk involved in this category of funds in the quest for high returns.
- Have the patience and sectoral understanding to 'extract value' from changing sector cycles.

Rethink before you invest

This is a sectoral/ thematic fund, therefore its NAV is likely to fluctuate a lot more than diversified equity funds.
Please do not use recent or past returns as the only criteria to evaluate this fund.
Healthcare fund carries Very High Risk.

Fund managers:

Chirag Dagli

Managing this fund since December 2020

See funds managed by him

See his investing philosophy

Managing this fund since December 2020

See funds managed by him

See his investing philosophy

Vinit Sambre

Managing this fund since November 2018

See funds managed by him

Managing this fund since November 2018

See funds managed by him

Jay Kothari

Managing this fund since November 2018

See funds managed by him

Managing this fund since November 2018

See funds managed by him

Chirag has a total work experience of Over 20 years.
He joined DSP Mutual Fund in November 2020 as Vice President in Equity Team.
Chirag has also worked with HDFC AMC Limited, Aviva life Insurance, ICICI Securities, Infinity.com Financial Services Limited, Global Markets - Deutsche Equities India Private Limited, Citigroup Global Markets India Private Limited and ICICI Securities.
He is a Chartered Accountant (ICAI India) and also holds a Bachelor of Commerce Degree.

Sr. No.	Scheme Name	Managing since	Period
Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement Different plans shall have a different expense structure. The performance details provided herein are of regular plan. Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Sr. No.

Scheme Name

Managing since

Period

1 Years

3 Years

5 Years

Scheme return (%)

Benchmark return (%)

Scheme return (%)

Benchmark return (%)

Scheme return (%)

Benchmark return (%)

Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement

Different plans shall have a different expense structure. The performance details provided herein are of regular plan.

Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Vinit joined DSPAM in July 2007, as Portfolio Analyst for the firm's Portfolio Management Services (PMS) division, which manages discretionary accounts and provides advisory services to institutional clients. As a research analyst, his focus was on sectors like Pharmaceuticals, Power Utilities, Chemicals, Fertilizers and Textiles. Vinit specializes in the small and mid cap space and has over 16 years of relevant work experience.
Previously, he was with DSP Merrill Lynch as a part of its Global Private Client business. He spent 20 months at DSP Merrill Lynch as Equity Strategist. Prior to DSP Merrill Lynch, he was employed with IL&FS Investsmart Limited as an Equity Analyst in their PMS division. He has also worked with UTI Investment Advisory Services as Equity Analyst for the offshore fund - India Growth Fund. Vinit is a Chartered Accountant from Institute of Chartered Accountant of India.

Note:
Gopal Agrawal managed the Schemes (i.e. DSP Top 100 Equity Fund, DSP Focus Fund, DSP Equity Savings Fund and DSP Regular Savings Fund) till May 31, 2020. Mr. Vinit Sambre is managing Schemes From June 1, 2020. (i.e. DSP Top 100 Equity Fund, DSP Focus Fund, DSP Equity Savings Fund and DSP Regular Savings Fund) with effect from June 1, 2020.

See offshore funds managed by him.

Sr. No.	Scheme Name	Managing since	Period
Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement Different plans shall have a different expense structure. The performance details provided herein are of regular plan. Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Sr. No.

Scheme Name

Managing since

Period

1 Years

3 Years

5 Years

Scheme return (%)

Benchmark return (%)

Scheme return (%)

Benchmark return (%)

Scheme return (%)

Benchmark return (%)

Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement

Different plans shall have a different expense structure. The performance details provided herein are of regular plan.

Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Jay Kothari, Vice President & Product Strategist -Jay has been with DSP Mutual Fund since May 2005, and has been with the Investment function since January 2011. Jay joined the firm as a member of the Sales team (Banking) in May 2005. Prior to joining DSPAM, Jay worked for Standard Chartered Bank for a year in the Priority Banking division. Jay completed his Bachelor of Management Studies (Finance & International Finance) from Mumbai University, followed by an MBA in Finance from Mumbai University.
Jay is currently the Dedicated Fund Manager for overseas investments for the following schemes of DSP Mutual Fund.

Sr. No.	Scheme Name	Managing since	Period
Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement Different plans shall have a different expense structure. The performance details provided herein are of regular plan. Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Sr. No.

Scheme Name

Managing since

Period

1 Years

3 Years

5 Years

Scheme return (%)

Benchmark return (%)

Scheme return (%)

Benchmark return (%)

Scheme return (%)

Benchmark return (%)

Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement

Different plans shall have a different expense structure. The performance details provided herein are of regular plan.

Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Portfolio

Prescribed asset allocation: 80% - 100% Equity and equity related securities of pharmaceutical and healthcare companies , 0% - 20% Equity and Equity related securities of other Companies , 0% - 20% Debt, securitized debt and Money Market Securities , 0% - 10% Units of REITs & InvITs

Current Allocation

as of Apr 30, 2023

Equity 99.77%
Debt / cash 0.39%

Equity
Debt / Cash

Top holdings

Sun Pharmaceutical Industries Limited

16.19%

Cipla Limited

9.73%

Apollo Hospitals Enterprise Limited

6.76%

Procter & Gamble Health Limited

5.95%

Lupin Limited

5.82%

Allocation by Market Cap

Large Cap

37.60%

Small Cap

26.40%

Mid Cap

21.00%

Uncategorized

14.80%

Top Sectors

Pharmaceuticals & Biotechnology

69.25%

Healthcare Services

13.71%

Healthcare Equipment & Supplies

8.58%

Pharmaceuticals & Biotechnology

3.38%

Insurance

2.10%

See all 26 holdings

Top holdings

TREPS / Reverse Repo Investments / Corporate Debt Repo

0.39%

Cash & cash equivalents

-0.16%

Credit rating profile

Cash & Equivalent

102.60%

Instrument break-up

TREPS

100.00%

See 1 holding

Indicators

Portfolio turnover ratio

0.22 last 12 months

Standard Deviation

15.31 %

Sharpe Ratio

0.78

Beta

0.88

R-Squared

85.46 %

Compare Performance

Performance highlights over last

for

investment

Cumulative returns on

Annual returns

Current value

Min CAGR:

MedianCAGR:

Max CAGR:

Good Returns

Negative Returns

vs Fixed Deposit

vs Category

vs Benchmark

Historical Returns (As per SEBI format)as of with investment of₹10,000

	This fund		S&P BSE HEALTHCARE (TRI) ^{^}		NIFTY 50 TRI ^#
	CAGR	Current Value	CAGR	Current Value	CAGR	Current Value

Income distribution Cum Capital Withdrawal (IDCW) Distributed

Record Date	IDCW per unit	NAV Before	NAV After

Chart type

Graph viewTable view

Invested as

Invested Amount

₹

Invested since

This fund

S&P BSE HEALTHCARE (TR…

NIFTY 50 TRI

Gold

PPF

	Funds	Annual returns	Current Value	Absolute Growth	IDCW paid

Chart type:

Returns RangesStatistics

Invested as

Invested Amount

₹

Invested period

Funds	Minimum	Median	Maximum	% times -ve returns	% times returns > 7%

Date of allotment: Nov 30, 2018.

Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement

Different plans shall have a different expense structure. The performance details provided herein are of Regular Plan.

Since inception returns have been calculated from the date of allotment till June 30, 2021

Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Rolling returns have been calculated based on returns from regular plan growth option.

^ Fund Benchmark # Standard Benchmark

Scheme disclaimers

Fund Details

Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
There is no assurance that the investment objective of the Scheme will be realized

Fund Type

Equity – Sectoral/Thematic

Pharma

An open ended equity scheme investing in healthcare and pharmaceutical sector

Riskometer

Level of Risk in the fund

View details

Investors understand that their
principal will be at Very High Risk

Minimum Investment

Rs. 100 Lumpsum
Rs. 100 SIP– 12 instalments
Rs. 100 Minimum Additional Purchase

Fund Documents

Fund presentation

KIM and Applications

Name	% of Net Assets
Sun Pharmaceutical Industries Limited	16.19%
Cipla Limited	9.73%
Procter & Gamble Health Limited	5.95%
Lupin Limited	5.82%
Alkem Laboratories Limited	5.02%
Alembic Pharmaceuticals Limited	4.91%
IPCA Laboratories Limited	4.51%
Suven Pharmaceuticals Limited	3.72%
Indoco Remedies Limited	3.29%
Zydus Lifesciences Limited	3.20%
Dr. Reddy's Laboratories Limited	2.72%
Aarti Drugs Limited	2.51%
Illumina Inc	1.14%
Pfizer Limited	0.46%
Taro Pharmaceutical Industries Limited	0.08%

Name

% of Net Assets

Sun Pharmaceutical Industries Limited

16.19%

Cipla Limited

9.73%

Procter & Gamble Health Limited

5.95%

Lupin Limited

5.82%

Alkem Laboratories Limited

5.02%

Alembic Pharmaceuticals Limited

4.91%

IPCA Laboratories Limited

4.51%

Suven Pharmaceuticals Limited

3.72%

Indoco Remedies Limited

3.29%

Zydus Lifesciences Limited

3.20%

Dr. Reddy's Laboratories Limited

2.72%

Aarti Drugs Limited

2.51%

Illumina Inc

1.14%

Pfizer Limited

0.46%

Taro Pharmaceutical Industries Limited

0.08%

Name	% of Net Assets
Apollo Hospitals Enterprise Limited	6.76%
Vijaya Diagnostic Centre Limited	3.09%
Syngene International Limited	2.04%
Kovai Medical Center and Hospital Limited	1.82%

Name

% of Net Assets

Apollo Hospitals Enterprise Limited

6.76%

Vijaya Diagnostic Centre Limited

3.09%

Syngene International Limited

2.04%

Kovai Medical Center and Hospital Limited

1.82%

Name	% of Net Assets
Intuitive Surgical Inc	3.72%
Globus Medical Inc	2.56%
Abbott Laboratories	2.30%

Name

% of Net Assets

Intuitive Surgical Inc

3.72%

Globus Medical Inc

2.56%

Abbott Laboratories

2.30%

Name	% of Net Assets
MANKIND PHARMA LIMITED^	3.38%

Name

% of Net Assets

MANKIND PHARMA LIMITED^

3.38%

Name	% of Net Assets
ICICI Lombard General Insurance Company Limited	2.10%

Name

% of Net Assets

ICICI Lombard General Insurance Company Limited

2.10%

Name	% of Net Assets
Global X Funds - Global X Genomics & Biotechnology ETF	1.61%

Name

% of Net Assets

Global X Funds - Global X Genomics & Biotechnology ETF

1.61%

Name	% of Net Assets
Medplus Health Services Limited	1.14%

Name

% of Net Assets

Medplus Health Services Limited

1.14%

Name	% of Net Assets
TREPS / Reverse Repo Investments / Corporate Debt Repo	0.39%

Email ID
Mobile no.

Email ID	ABH************[email protected]
Mobile no.	******6665

Email ID

ABH************[email protected]

Mobile no.

******6665

	Folio no.	Email ID	Mobile no.
	70****76	abh************[email protected]	******6665
	42***02	abh************[email protected]	******6665

Folio no.

Email ID

Mobile no.

70****76

abh************[email protected]

******6665

42***02

abh************[email protected]

******6665

DSP Healthcare Fund

DSP Healthcare Fund

This is an Equity Sectoral/Thematic, Pharma fund with S&P BSE HEALTHCARE (TRI) as its benchmark. The risk level for this fund is categorized as Very High Risk.

Things to know before you invest

What is in DSP Healthcare Fund?

Why should one invest in DSP Healthcare Fund?

Who should invest in DSP Healthcare Fund?

Rethink before you invest

Fund managers:

Portfolio

Current Allocation

Indicators

Compare Performance

Invested Amount

Invested Amount

Fund Details

Fund Details

Investment Objective

Fund Type

Riskometer

Minimum Investment

Fund Documents

Explore

Product Information

For Investors

For MF Distributors

Legal Information

Mobile Number

Email Address

Enter the OTP sent to

updated successfully.

Enter the OTP sent to

updated successfully.

You can opt for your email ID or mobile no. as username too.

DSP Healthcare Fund

DSP Healthcare Fund

This is an Equity Sectoral/Thematic, Pharma fund with S&P BSE HEALTHCARE (TRI) as its benchmark. The risk level for this fund is categorized as Very High Risk.

Things to know before you invest

What is in DSP Healthcare Fund?

Why should one invest in DSP Healthcare Fund?

Who should invest in DSP Healthcare Fund?

Rethink before you invest

Fund managers:

Portfolio

Current Allocation

Indicators

Compare Performance

Invested Amount

Invested Amount

Fund Details

Fund Details

Investment Objective

Fund Type

Riskometer

Minimum Investment

Fund Documents

To proceed, we need to first verify your KYC status.

As an additional authentication, we need to verify your contact details.